Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy resistant breast cancer

PURPOSE: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1) positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation mechanisms limit the duration of response. The clinical efficac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Wardell, Suzanne E., Ellis, Matthew J., Alley, Holly M., Eisele, Koleen, VanArsdale, Todd, Dann, Stephen G., Arndt, Kim T., Primeau, Tina, Griffin, Elizabeth, Shao, Jieya, Crowder, Robert, Lai, Jin-Ping, Norris, John D., McDonnell, Donald P., Li, Shunqiang
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4644714/
https://ncbi.nlm.nih.gov/pubmed/25991817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0360
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge